Effect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94780
Title:
Effect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty.
Authors:
Crowne, Elizabeth C; Wallace, W Hamish B; Moore, C; Mitchell, R; Robertson, W H; Holly, J M; Shalet, Stephen M
Abstract:
OBJECTIVE: To investigate the effect of low dose oxandrolone and testosterone on the pituitary-testicular and GH-IGF-I axes. DESIGN: Prospective double-blind placebo-controlled trial. PATIENTS: Sixteen boys with constitutional delay of growth and puberty (CDGP) with testicular volumes 4-6 ml were randomized to 3 months treatment: Group 1 (n = 5), daily placebo: Group 2 (n = 5), 2.5 mg oxandrolone daily or Group 3 (n = 6), 50 mg testosterone monthly intramuscular injections with assessment (growth, pubertal development and overnight hormone profiles) at 0, 3, 6 and 12 months. MAIN OUTCOME MEASURES: LH and GH profiles (15-minute samples) were analysed by peak detection (Pulsar), Fourier transformation and autocorrelation. Testosterone levels were measured hourly and insulin, SHBG, IGF-I, and IGFBP-3 levels at 0800 h. Statistical analysis was by multivariate analysis of variance for repeated measures. RESULTS: LH and testosterone parameters increased significantly with time in all 16 (LH AUC, P < 0.001; peak amplitude, P = 0.02; number of peaks, P = 0.02; testosterone AUC, P = 0.02; morning testosterone, P = 0.002). In Group 2, however, LH and testosterone parameters decreased at 3 months followed by a rebound increase at 6 and 12 months. SHBG levels were markedly reduced at 3 months (P = 0.006) and a wider range of dominant GH frequencies was present although GH AUC was not increased until 6 months, with an increase in GH pulse frequency but not amplitude. IGF-I levels were increased at both 3 and 12 months. In Group 3, pituitary-testicular suppression was not apparent, but GH levels increased with an increase in GH amplitude at 3 and 12 months. CONCLUSION: Oxandrolone transiently suppressed the pituitary-testicular axis and altered GH pulsatility. Testosterone increased GH via amplitude modulation.
Affiliation:
Department of Endocrinology, Christie Hospital Trust, Manchester, UK.
Citation:
Effect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty. 1997, 46 (2):209-16 Clin. Endocrinol. (Oxf)
Journal:
Clinical Endocrinology
Issue Date:
Feb-1997
URI:
http://hdl.handle.net/10541/94780
PubMed ID:
9135704
Type:
Article
Language:
en
ISSN:
0300-0664
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCrowne, Elizabeth Cen
dc.contributor.authorWallace, W Hamish Ben
dc.contributor.authorMoore, Cen
dc.contributor.authorMitchell, Ren
dc.contributor.authorRobertson, W Hen
dc.contributor.authorHolly, J Men
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2010-03-23T17:26:48Z-
dc.date.available2010-03-23T17:26:48Z-
dc.date.issued1997-02-
dc.identifier.citationEffect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty. 1997, 46 (2):209-16 Clin. Endocrinol. (Oxf)en
dc.identifier.issn0300-0664-
dc.identifier.pmid9135704-
dc.identifier.urihttp://hdl.handle.net/10541/94780-
dc.description.abstractOBJECTIVE: To investigate the effect of low dose oxandrolone and testosterone on the pituitary-testicular and GH-IGF-I axes. DESIGN: Prospective double-blind placebo-controlled trial. PATIENTS: Sixteen boys with constitutional delay of growth and puberty (CDGP) with testicular volumes 4-6 ml were randomized to 3 months treatment: Group 1 (n = 5), daily placebo: Group 2 (n = 5), 2.5 mg oxandrolone daily or Group 3 (n = 6), 50 mg testosterone monthly intramuscular injections with assessment (growth, pubertal development and overnight hormone profiles) at 0, 3, 6 and 12 months. MAIN OUTCOME MEASURES: LH and GH profiles (15-minute samples) were analysed by peak detection (Pulsar), Fourier transformation and autocorrelation. Testosterone levels were measured hourly and insulin, SHBG, IGF-I, and IGFBP-3 levels at 0800 h. Statistical analysis was by multivariate analysis of variance for repeated measures. RESULTS: LH and testosterone parameters increased significantly with time in all 16 (LH AUC, P < 0.001; peak amplitude, P = 0.02; number of peaks, P = 0.02; testosterone AUC, P = 0.02; morning testosterone, P = 0.002). In Group 2, however, LH and testosterone parameters decreased at 3 months followed by a rebound increase at 6 and 12 months. SHBG levels were markedly reduced at 3 months (P = 0.006) and a wider range of dominant GH frequencies was present although GH AUC was not increased until 6 months, with an increase in GH pulse frequency but not amplitude. IGF-I levels were increased at both 3 and 12 months. In Group 3, pituitary-testicular suppression was not apparent, but GH levels increased with an increase in GH amplitude at 3 and 12 months. CONCLUSION: Oxandrolone transiently suppressed the pituitary-testicular axis and altered GH pulsatility. Testosterone increased GH via amplitude modulation.en
dc.language.isoenen
dc.subject.meshAdolescent-
dc.subject.meshAnabolic Agents-
dc.subject.meshDouble-Blind Method-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshGrowth Disorders-
dc.subject.meshGrowth Hormone-
dc.subject.meshHumans-
dc.subject.meshLuteinizing Hormone-
dc.subject.meshMale-
dc.subject.meshOxandrolone-
dc.subject.meshPituitary Gland-
dc.subject.meshProspective Studies-
dc.subject.meshPuberty, Delayed-
dc.subject.meshSecretory Rate-
dc.subject.meshTestis-
dc.subject.meshTestosterone-
dc.titleEffect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital Trust, Manchester, UK.en
dc.identifier.journalClinical Endocrinologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.